Tharimmune, Inc. (THAR)

Tharimmune, Inc. (THAR) Healthcare & Pipeline Overview

Tharimmune, Inc. is a clinical-stage biotechnology firm concentrating on rare, inflammatory, and oncologic diseases. With a pre-clinical immuno-oncology pipeline featuring TH104, TH3215, TH0059, and TH1940, the company aims to address unmet needs in liver-related conditions, solid tumors, and PD-1 targeting, operating within the competitive biotechnology sector.

What Is the Investment Thesis for THAR?

Tharimmune, Inc. presents a high-risk, high-reward investment opportunity typical of early-stage biotechnology companies. The company's value is primarily driven by its pre-clinical immuno-oncology pipeline, including TH104, TH3215, TH0059, and TH1940. Successful progression of these candidates through clinical trials represents a significant value catalyst. Key milestones to watch include the initiation of Phase 1 trials for TH104 in liver-related conditions and the advancement of TH3215 and TH0059 towards IND-enabling studies for solid tumors. The collaboration with Minotaur Therapeutics for targeted biologics adds another layer of potential value creation. However, the company faces substantial risks, including the inherent uncertainty of drug development, potential clinical trial failures, and the need for significant additional capital to fund operations. With a market cap of $139.94M and a beta of 1.45, THAR exhibits significant volatility. Investors should carefully consider the company's early stage, limited resources, and the competitive landscape before investing.

Based on FMP financials and quantitative analysis

THAR Key Highlights

• Tharimmune, Inc. is a clinical-stage biotechnology company focused on rare, inflammatory, and oncologic diseases.
• The company's pre-clinical immuno-oncology pipeline includes TH104, TH3215, TH0059, and TH1940.
• Tharimmune has a research collaboration and product license agreement with Minotaur Therapeutics, Inc.
• The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
• Tharimmune has a market capitalization of $139.94M and a beta of 1.45.

Who Are THAR's Competitors?

THAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are THAR's Key Strengths?

• Focus on rare, inflammatory, and oncologic diseases.
• Pre-clinical immuno-oncology pipeline.
• Research collaboration with Minotaur Therapeutics.
• Experienced leadership in biotechnology.

What Are THAR's Weaknesses?

• Early-stage clinical development.
• Limited financial resources.
• Small number of employees.
• Dependence on successful clinical trials.

What Could Drive THAR Stock Higher?

• Initiation of Phase 1 clinical trials for TH104 in liver-related conditions.
• Advancement of TH3215 and TH0059 towards IND-enabling studies for solid tumors.
• Progress in research collaboration with Minotaur Therapeutics for targeted biologics.
• Publication of pre-clinical data for pipeline candidates.
• Potential for new strategic partnerships to expand pipeline.

What Are the Key Risks for THAR?

• Financial-distress signal — its Altman Z-Score of 0.02 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-36.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for pipeline candidates.
• Regulatory hurdles and delays in drug development.
• Competition from larger biotechnology companies.
• Need for additional capital to fund operations.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for THAR?

• Advancement of TH104 for Liver-Related Conditions: Tharimmune's TH104 product candidate targets liver-related and other pruritogenic inflammatory conditions. The market for treatments addressing these conditions is substantial, driven by the increasing prevalence of liver diseases and the unmet need for effective therapies. Successful completion of pre-clinical studies and initiation of Phase 1 clinical trials could significantly increase the company's value. The timeline for potential commercialization is estimated at 5-7 years, contingent on positive clinical trial outcomes and regulatory approvals. Competition in this space includes companies developing novel anti-inflammatory agents and liver-targeted therapies.
• Development of TH3215 and TH0059 for Solid Tumors: Tharimmune is developing TH3215 and TH0059 as product candidates for the treatment of various solid tumors. The global market for solid tumor therapies is one of the largest in oncology, with significant opportunities for innovative treatments. The company's focus on specific tumor types and mechanisms of action could differentiate its candidates from existing therapies. Advancement of these candidates towards IND-enabling studies and subsequent clinical trials is a key growth driver. The timeline for potential commercialization is estimated at 6-8 years, pending successful clinical development and regulatory approvals. Competitors include major pharmaceutical companies and other biotechnology firms developing novel cancer therapies.
• Targeting PD-1 with TH1940: Tharimmune's TH1940 targets programmed cell death protein 1 (PD-1), a key immune checkpoint. PD-1 inhibitors have revolutionized cancer therapy, and there remains a significant opportunity to develop novel agents that enhance their efficacy or overcome resistance. The company's approach to targeting PD-1 could offer advantages over existing therapies. Pre-clinical studies and subsequent clinical trials will be critical to demonstrating the potential of TH1940. The timeline for potential commercialization is estimated at 5-7 years, contingent on positive clinical trial results and regulatory approvals. Competition in this space includes established pharmaceutical companies with approved PD-1 inhibitors and other biotechnology firms developing novel immunotherapies.
• Strategic Collaboration with Minotaur Therapeutics: Tharimmune's research collaboration and product license agreement with Minotaur Therapeutics, Inc. provides access to proprietary targeted biologics. This collaboration expands the company's pipeline and diversifies its technology platform. The development of these targeted biologics could lead to new therapeutic candidates for various diseases. The timeline for potential commercialization depends on the specific targets and mechanisms of action of the biologics. This collaboration strengthens Tharimmune's position in the biotechnology industry and provides access to valuable intellectual property and expertise. The financial terms of the agreement and the potential for future milestones and royalties are important factors to consider.
• Expansion into Rare Diseases: Tharimmune's focus on rare diseases represents a significant growth opportunity. The market for rare disease therapies is growing rapidly, driven by increased awareness, regulatory incentives, and advances in genetic diagnostics. The company's pipeline candidates could address unmet needs in specific rare diseases, providing opportunities for orphan drug designation and accelerated regulatory pathways. Successful development and commercialization of therapies for rare diseases could generate significant revenue and enhance the company's reputation. The timeline for potential commercialization depends on the specific rare diseases targeted and the regulatory pathways pursued. Competition in this space includes other biotechnology companies focused on rare disease therapies.

What Opportunities Does THAR Have?

• Advancement of pipeline candidates through clinical trials.
• Expansion of research collaborations.
• Potential for orphan drug designation.
• Partnerships with larger pharmaceutical companies.

What Threats Does THAR Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger biotechnology companies.
• Need for additional capital.

What Are THAR's Competitive Advantages?

• Proprietary pre-clinical immuno-oncology pipeline.
• Research collaboration with Minotaur Therapeutics, Inc.
• Focus on specific therapeutic areas with unmet needs.
• Intellectual property protection for therapeutic candidates.

What Does THAR Do?

Tharimmune, Inc., headquartered in Bridgewater, New Jersey, is a clinical-stage biotechnology company dedicated to the development of novel therapeutic candidates. The company focuses on addressing rare, inflammatory, and oncologic diseases, aiming to provide innovative solutions for conditions with limited treatment options. Incorporated in 2017, Tharimmune has evolved from its previous identity as Hillstream BioPharma, Inc., rebranding in September 2023 to reflect its refined strategic direction. Tharimmune's core activities revolve around its pre-clinical immuno-oncology pipeline, which includes several promising product candidates. TH104 is being developed for the treatment of liver-related and other pruritogenic inflammatory conditions. TH3215 and TH0059 are targeted towards various solid tumors, representing a broad approach to cancer therapy. TH1940 aims to target programmed cell death protein 1 (PD-1), a key immune checkpoint, with the goal of enhancing anti-tumor immune responses. Tharimmune also engages in strategic collaborations to expand its capabilities and pipeline. The company has a research collaboration and product license agreement with Minotaur Therapeutics, Inc., focusing on the development of proprietary targeted biologics. This collaboration underscores Tharimmune's commitment to leveraging external expertise and resources to accelerate its drug development programs. With a small team of 2 employees, Tharimmune operates with a lean structure, emphasizing focused execution and strategic partnerships to advance its therapeutic candidates through the development pipeline.

What Products and Services Does THAR Offer?

• Develop therapeutic candidates for rare diseases.
• Develop therapeutic candidates for inflammatory diseases.
• Develop therapeutic candidates for oncologic diseases.
• Focus on pre-clinical immuno-oncology pipeline.
• Develop TH104 for liver-related and pruritogenic inflammatory conditions.
• Develop TH3215 and TH0059 for various solid tumors.
• Develop TH1940, which targets programmed cell death protein 1 (PD-1).
• Engage in research collaboration with Minotaur Therapeutics, Inc.

How Does THAR Make Money?

• Develop and license therapeutic candidates.
• Generate revenue through research collaborations.
• Seek strategic partnerships to expand pipeline.
• Focus on pre-clinical development and early-stage clinical trials.

What Industry Does THAR Operate In?

Tharimmune operates within the highly competitive and dynamic biotechnology industry. This sector is characterized by intense research and development, high regulatory hurdles, and significant capital requirements. The market for immuno-oncology therapies is experiencing substantial growth, driven by advances in understanding the role of the immune system in cancer and the development of novel immunotherapies. Companies like Tharimmune are focused on developing innovative approaches to target specific pathways and enhance anti-tumor immune responses. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in specific therapeutic areas. Success in this industry depends on scientific innovation, clinical trial execution, and strategic partnerships.

Who Are THAR's Key Customers?

• Future patients with rare diseases.
• Future patients with inflammatory diseases.
• Future patients with oncologic diseases.

ROE -37%Key Financial Metrics

Return on equity for Tharimmune, Inc. stands at -36.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 37.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.

How Tharimmune, Inc. Is Valued

Tharimmune, Inc. carries a market capitalization of $139.94M, placing it in the micro-cap category. Relative to its peer group, THAR's quantitative score of 49/100 is below the peer average of 76/100.

F-Score 2/9Financial Health

Tharimmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.02 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Tharimmune, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.75.

THAR Financials

THAR Latest News

No recent news available for THAR.

THAR Analyst Consensus

THAR MoonshotScore

What Investors Ask About Tharimmune, Inc. (THAR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources